Microglial impact on remyelination

小胶质细胞对髓鞘再生的影响

基本信息

  • 批准号:
    10614374
  • 负责人:
  • 金额:
    $ 48.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-06-15 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Enhancing remyelination is a critical strategy for restoring brain function after demyelination in multiple sclerosis (MS) patients; however, despite concerted efforts, the ability to stimulate remyelination in MS brain has remained elusive. While signaling pathways that promote oligodendrocyte precursor differentiation have been identified, the experimental milieux under investigation do not replicate the mechanisms limiting remyelination following MS-specific inflammatory CNS injuries. The current proposal builds on our new models of demyelination/remyelination using pathogenic recombinant antibodies (rAbs) generated from MS patients. Myelin-specific MS rAbs direct complement-mediated demyelination in vivo and ex vivo, all of which spontaneously repair in association with microglial activation. However, demyelinated explants that are continuously exposed to myelin-specific MS rAb fail to activate microglia, and oligodendrocyte maturation is inhibited. Similarly, targeted depletion of microglia following rAb-mediated demyelination blocks oligodendrocyte maturation preventing active remyelination. Using single cell RNASeq (scRNASeq) on microglia isolated from remyelinating explants, we identified transcriptionally distinct microglial subsets that are associated with successful or failed remyelination. Hence, we hypothesize that microglial signals are critical for oligodendrocyte responses during the transition from early myelinating to actively myelinating oligodendrocyte, and myelin-specific MS autoantibody modulates these signals to arrest remyelination. To test our hypothesis, we propose three complementary specific aims. In Aim 1, we will evaluate microglial and oligodendrocyte responses in in vivo models of MS rAb-mediated demyelination and compare those responses to those seen in toxin-mediated demyelination. Intrathalamic or corpus callosum injection of myelin-specific MS rAb plus HC will be performed in conjunction with pharmacologic microglial depletion and chronic administration of MS rAb to validate the impact of microglial responses on remyelination in the intact nervous system. Comparable studies will be done following lysolecithin-induced demyelination, which has a very different time course of microglial activation and remyelination. In Aim 2, we will study the dynamics of demyelination, microglial responses and oligodendrocyte regeneration in situ using intravital imaging following cortical demyelination. This real-time analysis of myelin loss, microglial activation and remyelination will be compared to that seen following cuprizone-mediated demyelination. Finally, in Aim 3, we will investigate the mechanisms by which microglia impact remyelination using ex vivo cerebellar slices demyelinated with myelin- specific rAb plus human complement (HC). We will focus on investigating the role of several microglial genes identified by scRNASeq that are expected to promote or impair remyelination. Normal appearing white matter and MS lesion tissue with varying degrees of demyelination and remyelination will be evaluated to determine the abundance and localization of functionally-important microglial subsets. The results of these studies will provide insights into novel mechanisms controlling remyelination after inflammatory injury. In addition, the knowledge gained may identify novel therapeutic approaches that will result in clinically-meaningful myelin repair.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jeffrey L Bennett其他文献

Periodic Alternating Nystagmus, Ataxia, and Spasticity: A Unique Presentation of Spastic Paraplegia 7‐Related Hereditary Spastic Paraplegia
周期性交替眼球震颤、共济失调和痉挛:痉挛性截瘫的独特表现 7 相关遗传性痉挛性截瘫
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    4
  • 作者:
    Jordan L Hickman;Marrisa Lafreniere;Jeffrey L Bennett;Emily Forbes;J. Feuerstein
  • 通讯作者:
    J. Feuerstein
Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica
  • DOI:
    10.1186/s40478-025-02019-7
  • 发表时间:
    2025-06-12
  • 期刊:
  • 影响因子:
    5.700
  • 作者:
    Katherine S Given;Elizabeth G Acker;Wendy B Macklin;Dan Carlin;Gregory P. Owens;Jeffrey L Bennett
  • 通讯作者:
    Jeffrey L Bennett

Jeffrey L Bennett的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jeffrey L Bennett', 18)}}的其他基金

In vivo modeling of autoantibody-induced optic neuritis
自身抗体诱导的视神经炎的体内模型
  • 批准号:
    10429925
  • 财政年份:
    2021
  • 资助金额:
    $ 48.74万
  • 项目类别:
Microglial impact on remyelination
小胶质细胞对髓鞘再生的影响
  • 批准号:
    10175074
  • 财政年份:
    2020
  • 资助金额:
    $ 48.74万
  • 项目类别:
Microglial impact on remyelination
小胶质细胞对髓鞘再生的影响
  • 批准号:
    10357946
  • 财政年份:
    2020
  • 资助金额:
    $ 48.74万
  • 项目类别:
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica
视神经脊髓炎的体液免疫、星形胶质细胞损伤和脱髓鞘
  • 批准号:
    9898380
  • 财政年份:
    2018
  • 资助金额:
    $ 48.74万
  • 项目类别:
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica
视神经脊髓炎的体液免疫、星形胶质细胞损伤和脱髓鞘
  • 批准号:
    10372070
  • 财政年份:
    2018
  • 资助金额:
    $ 48.74万
  • 项目类别:
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica
视神经脊髓炎的体液免疫、星形胶质细胞损伤和脱髓鞘
  • 批准号:
    10132323
  • 财政年份:
    2018
  • 资助金额:
    $ 48.74万
  • 项目类别:
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica
视神经脊髓炎的体液免疫、星形胶质细胞损伤和脱髓鞘
  • 批准号:
    8786891
  • 财政年份:
    2013
  • 资助金额:
    $ 48.74万
  • 项目类别:
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica
视神经脊髓炎的体液免疫、星形胶质细胞损伤和脱髓鞘
  • 批准号:
    8418576
  • 财政年份:
    2013
  • 资助金额:
    $ 48.74万
  • 项目类别:
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica
视神经脊髓炎的体液免疫、星形胶质细胞损伤和脱髓鞘
  • 批准号:
    9198012
  • 财政年份:
    2013
  • 资助金额:
    $ 48.74万
  • 项目类别:
Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis Optica
视神经脊髓炎的体液免疫、星形胶质细胞损伤和脱髓鞘
  • 批准号:
    8601080
  • 财政年份:
    2013
  • 资助金额:
    $ 48.74万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 48.74万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 48.74万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 48.74万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.74万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了